Drug Profile
Poloxamer 188 - Phrixus Pharmaceuticals
Alternative Names: Carmeseal; Carmeseal-HF; Carmeseal-MD; P-188; P-188 NFLatest Information Update: 25 Jan 2023
Price :
$50
*
At a glance
- Originator Phrixus Pharmaceuticals
- Developer Ethicor Pharma; Phrixus Pharmaceuticals; University of Michigan
- Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
- Mechanism of Action Blood cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Duchenne muscular dystrophy
- No development reported Heart failure
Most Recent Events
- 01 Sep 2021 Phrixus Pharmaceuticals terminates a phase II trial in Duchenne muscular dystrophy (In adolescents, In adults, In children) in USA (SC), due to lack of funding(NCT03558958)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Duchenne muscular dystrophy in European Union (SC)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Heart-failure in USA (IV)